“Plaintiffs Boehringer Ingelheim Animal Health USA Inc. and Boehringer Ingelheim Vetmedica GmbH (collectively, “Boehringer”), and Defendant Dechra Veterinary Products, LLC (“Dechra”), by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and injunction in this action as follows: IT IS, this 31st day of October, 2025 HEREBY ORDERED, ADJUDGED AND DECREED that: 1. For purposes of this action only, this Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over Boehringer and Dechra. 2. As used in this Consent Judgment and Order of Permanent Injunction, (i) the term “the Asserted Patent” means U.S. Patent No. 8,846,679, which Dechra agrees is valid and enforceable, (ii) the term “Dechra ANADA Products” shall mean the products sold, offered for sale or distributed pursuant to Abbreviated New Animal Drug Application No. 200778-A-0000- OT, and (iii) the term “Affiliate” shall mean any entity controlling, controlled by, or under common control with a Party, but only as long as such control continues, where “control” means: (1) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, or the right to vote for or appoint a majority of the board of directors or other governing body of such entity; or (2) the power to directly, or indirectly direct or cause the direction of the management and policies of such entity by any means whatsoever. 3. Except as specifically authorized by Boehringer, Dechra, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, importing or distributing the Dechra ANADA Products, on its own part or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with Dechra or its Affiliates, through and until the expiration of the Asserted Patent, including any patent term extension and/or patent term adjustment. If Boehringer becomes entitled to any other regulatory exclusivities that are not referenced herein, Boehringer may apply to the Court for modification of the injunction to incorporate such specified exclusivity. 4. The Parties agree that, in the event of a violation of the terms of this Consent Judgment and Order of Permanent Injunction, jurisdiction and venue for an action to enforce performance under this Consent Judgment and Order of Permanent Injunction, including for a preliminary injunction against the breaching conduct, exists in this District Court, and the Parties hereby waive any and all defenses based on personal jurisdiction and venue. 5. Nothing in this Consent Judgment and Order of Permanent Injunction prohibits Dechra or its Affiliates from maintaining a Paragraph IV Certification to the Asserted Patent or prohibits FDA from granting final approval to Dechra’s ANADA No. 200778-A-0000-OT. 6. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and Order of Permanent Injunction. The Complaint and all remaining claims, counterclaims, or affirmative defenses in this action are dismissed without prejudice and without costs, disbursements, or attorney fees to any party.”